Antibacterial in your toothpaste may combat severe lung disease

May 17, 2018 by Sarina Gleason, Michigan State University
Comparison of the cystic fibrosis bacteria, which becomes a green color under fluorescent light, shown before and after treatment. Far right column -- untreated bacteria. Second column -- bacteria treated with tobramycin alone showing some of the bacteria still remaining. Third column -- bacteria treated with triclosan alone showing the majority of the bacteria still remaining. Far left column -- bacteria treated with tobramycin and triclosan showing the effectiveness of the combination treatment. Credit: Michigan State University

A common antibacterial substance found in toothpaste may combat life-threatening diseases such as cystic fibrosis, or CF, when combined with an already FDA-approved drug.

Michigan State University researchers have found that when , a substance that reduces or prevents bacteria from growing, is combined with an antibiotic called tobramycin, it kills the cells that protect the CF bacteria, known as Pseudomonas aeruginosa, by up to 99.9 percent.

CF is a with one in every 2,500 to 3,500 people diagnosed with it at an early age. It results in a thick mucus in the lungs, which becomes a magnet for bacteria.

These bacteria are notoriously difficult to kill because they are protected by a slimy barrier known as a biofilm, which allows the disease to thrive even when treated with antibiotics.

"The problem that we're really tackling is finding ways to kill these biofilms," said Chris Waters, lead author of the study and a microbiology professor.

According to Waters, there are many common biofilm-related infections that people get such as and swollen, painful gums caused by gingivitis. But more serious, potentially fatal diseases join the ranks of CF including endocarditis, or inflammation of the heart, as well as infections from artificial hip and pacemaker implants.

The research is published in the journal Antimicrobial Agents and Chemotherapy.

Waters and his co-authors, Michael Maiden and Alessandra Hunt, grew 6,000 biofilms in petri dishes, added in tobramycin along with many different compounds, to see what worked better at killing the bacteria. Twenty-five potential compounds were effective, but one stood out.

"It's well known that triclosan, when used by itself, isn't effective at killing Pseudomonas aeruginosa," Hunt said, a post-doctoral associate of microbiology and molecular genetics. "But when I saw it listed as a possible compound to use with tobramycin, I was intrigued. We found triclosan was the one that worked every time."

Triclosan has been used for more than 40 years in soaps, makeup and other commercial products because of its antibacterial properties. Recently, the FDA ruled to limit its use in soaps and hand sanitizers due to insufficient data on its increased effectiveness and concern that it was being overused. Clear evidence has shown, though, that its use in toothpaste is safe and highly effective in fighting gingivitis, and it is still approved for use.

"Limiting its use is the right thing to do," Maiden said, a graduate student in medicine. "The key is to avoid creating resistance to a substance so when it's found in numerous products, the chances of that happening increase."

Tobramycin is currently the most widely used treatment for CF, but it typically doesn't clear the lungs of , Waters said. Patients typically inhale the drug, yet find themselves chronically infected their whole lives, eventually needing a lung transplant.

"Most transplants aren't a viable option though for these patients and those who do have a transplant see a 50 percent failure rate within five years," he said. "The other issue is that tobramycin can be toxic itself."

Known side effects from the drug include kidney toxicity and hearing loss.

Michigan State University microbiology professor Chris Waters (pictured left), with research associates Micheal Maiden and Alessandra Hunt, have found that a common antibacterial substance found in toothpaste may combat life-threatening diseases such as cystic fibrosis when combined with the already FDA-approved antibiotic tobramycin. Credit: Derrick Turner
"Our triclosan finding gives doctors another potential option and allows them to use significantly less of the tobramycin in treatment, potentially reducing its use by 100 times," Hunt said.

Within the next year, Waters and his colleagues will begin testing the effectiveness of the combination therapy on mice with hopes of it heading to a human trial soon after since both drugs are already FDA approved.

Just brushing your teeth with toothpaste that has triclosan won't help to treat lung infections though, Maiden said.

"We're working to get this potential therapy approved so we can provide a new treatment option for CF patients, as well as treat other biofilm infections that are now untreatable. We think this can save lives."

Explore further: Ban on triclosan shows need for new chemicals to demonstrate efficacy and safety

Related Stories

Ban on triclosan shows need for new chemicals to demonstrate efficacy and safety

December 6, 2016
A new commentary from Patrick McNamara and Stuart Levy cautions that the Food and Drug Administration's ban on triclosan and 18 other biocidal chemicals that promote antibiotic resistance is only a starting point. Triclosan's ...

Why you should dispense with antibacterial soaps

September 14, 2016
An FDA ruling on Sept. 2 bans the use of triclosan, triclocarban and 17 other antiseptics from household soaps because they have not been shown to be safe or even have any benefit.

Group urges tougher limits on chemical in shampoos, cosmetics

June 21, 2017
(HealthDay)—The germ-fighting chemical triclosan has got to go, an international coalition of scientists claims.

Recommended for you

Machine learning can be used to predict which patients require emergency admission

November 20, 2018
Machine learning—a field of artificial intelligence that uses statistical techniques to enable computer systems to 'learn' from data—can be used to analyse electronic health records and predict the risk of emergency hospital ...

Researchers stop 'sneaky' cancer cells in their tracks

November 20, 2018
A new study by University of Minnesota biomedical engineers shows how they stopped cancer cells from moving and spreading, even when the cells changed their movements. The discovery could have a major impact on millions of ...

A Trojan horse delivery method for miRNA-enriched extracellular vesicles

November 20, 2018
A method for large-scale production of extracellular vesicles enriched with specific microRNAs (miRNAs) has been developed in the Wake Forest Institute for Regenerative Medicine (WFIRM) labs, offering a manufacturing standardization ...

Researchers hope to be able to replace dysfunctional brain cells

November 20, 2018
A new study by researchers at Karolinska Institutet supports the theory that replacement of dysfunctional immune cells in the brain has therapeutic potential for neurodegenerative diseases like ALS and Alzheimer's disease. ...

RNAi therapy mitigates preeclampsia symptoms

November 19, 2018
A collaboration of scientists from the University of Massachusetts Medical School, Beth Israel Deaconess Medical Center and Western Sydney University, have shown that an innovative new type of therapy using small interfering ...

Skeletal imitation reveals how bones grow atom-by-atom

November 19, 2018
Researchers from Chalmers University of Technology, Sweden, have discovered how our bones grow at an atomic level, showing how an unstructured mass orders itself into a perfectly arranged bone structure. The discovery offers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.